



Although pancreatic ductal adenocarcinoma (PDAC) represents less than 2% of new cancers, it is constantly increasing (14,000 new cases/year in France) and is one of the main causes of cancer-related mortality. Indeed, the vast majority of pancreatic cancers are locally advanced or metastatic at diagnosis. The incidence almost equal to the mortality rate proves the incurable nature of this cancer. Despite the progress made in understanding the pathogenesis of PDAC, and the improvement of treatment regimens, the survival rate after treatment remains poor. Thus, basic and clinical research is still the best allies of patients and medical teams to make significant breakthroughs and improve the prognosis of this dreaded disease. The "Pancreatic Cancer symposium 2023" will be the third edition of an international meeting that brings together researchers and clinicians at the forefront of knowledge of pancreatic cancer. It is organized by a non-profit group of French researchers (AFRCP). Considering recent state-of-the-art, this event will focus on current and future noteworthy themes in the field. In particular, the following interdisciplinary sessions will be proposed to the international research community: (I) new modalities for PDAC clinical management, (II) identification and targeting of new tumor vulnerabilities, (III) exploration of the primary and the secondary tumor microenvironment, (IV) new modalities and technologies for pancreatic cancer research, with a special round table on PDAC organoïds, (V) PDAC prevention and early disease. A final session (VI) will be centered on the involvement of the patients in research design.

Organizing Committee

AFRC

ASSUMPTION AND APPRIANCE FOR U. A TOHIOS

SUIL COAST DO JONES AND APPRIANCE FOR U. A TOHIOS

ASSUMPTION AND APPRIANCE FOR U. A T



PRELIMINARY PROGRAM



MONDAY, OCTOBER 16™

11.30 (a) REGISTRATION

& WELCOME OF THE PARTICIPANTS

Opening Symposium
by Pr. Louis BUSCAIL,

President of the AFRCP, Toulouse
University Hospital, France

12.00 @ LUNCH BREAK

SESSION I

NEW MODALITIES FOR PDAC CLINICAL MANAGEMENT

15.10 LECTURE

therapeutic innovation
for metastatic cancer
By Pr. Pascal Hammel, Hôpital
Paul-Brousse, Villejuif, France

15.40 EDECTURE

Epidemiology France vs Europe,
or Europe vs North America
By Pr. Isabelle Baldi,
ISPED, Bordeaux, France

16.10 (b) COFFEE BREAK

17.10 ECTURE

The patient in the therapeutic decision: the need to risk balance

By Thibaud Haaser,

Bordeaux University Hospital,

Bordeaux, France

17.40 DEND OF THE DAY

PRELIMINARY PROGRAM (1)

TUESDAY, OCTOBER 17TH

08.30 @ OPENING

SESSION II

IDENTIFICATION AND TARGETING OF NEW TUMOR VULNERABILITIES

09.00 @ CONFERENCE

New interdisciplinary technological approaches applied to the study of the tumor microenvironment By Dr. Alex Shalek, Cambridge, MA, USA

09.40 D LECTURE

The microbiota a new actor

in the PDAC

By Pr. Cindy Neuzillet,

Institut Curie, Paris France

10.10 P Talk from abstracts

10.20 P Talk from abstracts

10.30 P Talk from abstracts

10.40 🕑 COFFEE BREAK

11.10 ELECTURE
The promises of virotherapy
By Dr. Pierre Cordelier,
CRCT, Toulouse, France

11.40 P Talk from abstracts

11.50 P Talk from abstracts

12.00 P Talk from abstracts

12.10 (a) LUNCH BREAK

SESSION III

EXPLORATION OF THE PRIMARY AND SECONDARY TUMOR MICROENVIRONMENT

13.40 CONFERENCE
Stroma and resistance
By Dr. Corinne Bousquet,
CRCT, Toulouse, France

14.20 ELECTURE

Multidisciplinary studies of stem
cells and tumor heterogeneity
By Pr. Axel Behrens, Institute
of Cancer research, London, UK

14.50 P Talk from abstracts

15.00 P Talk from abstracts

15.10 P Talk from abstracts

15.20 🖒 COFFEE BREAK

15.40 ELECTURE
Liver determinism of pancreatic
cancer metastases
By Pr. Michael Schmid, University
of Liverpool, Liverpool UK

16.10 P Talk from abstracts

16.20 P Talk from abstracts

16.30 P Talk from abstracts

16.40 P END OF THE DAY

20.00 GALA DINNER



WEDNESDAY, OCTOBER 18TH

08.30 (a) OPENING

SESSION IV

NEW MODALITIES AND TECHNOLOGIES FOR PANCREATIC CANCER RESEARCH

09.00 @ CONFERENCE

Genetic and chemical proteomic approaches to delineate the role of ROS during pancreatic tumorigenesis By Dr. Christine Chio, Columbia University, New York, USA

09.40 DECTURE

Targeting of CD39 et CD73

By Pr. Michael Schmid, University

of Liverpool, Liverpool UK

10.10 P Talk from abstracts

10.20 P Talk from abstracts

10.30 P Talk from abstracts

10.40 (b) COFFEE BREAK

11.10 ROUND TABLE
Organoids as PDAC models
By Dr. Nathalie Vergnolle, Toulouse

PDAC MODELS: Dr. Audrey Vincent, Lille, Dr. Fanny Jolin, Marseille

11.40 P Talk from abstracts

11.50 P Talk from abstracts

12.00 P Talk from abstracts

12.10 (a) LUNCH BREAK

SESSION V

PDAC PREVENTION AND EARLY DISEASE

13.40 CONFERENCE
Early detection
of pancreatic cancer
By Pr. Michael Goggins,
The Johns Hopkins Hospital,
Baltimore, MD, USA

14.20 New methods of early detection and the development of personalized therapies

By Pr. Dieter Saur, Central Institute for Translational Cancer Research, Munich, Germany

14.50 **Talk from abstracts**

15.00 **Talk from abstracts**

15.10 P Talk from abstracts

15.20 🖒 COFFEE BREAK

16.20 P Talk from abstracts

16.30 P Talk from abstracts

SESSION VI

THE ROLE OF PATIENTS IN CANCER RESEARCH

16.40 ROUND TABLE

Consideration of the patient in European research protocols

By Cyril Sarrauste, from the association patients en réseau with the DICE association,

digestive cancers.eu

CALL FOR ABSTRACTS

You are welcome to submit an abstract to present your experience and share your expertise.

Both AFRCP and non-AFRCP members are allowed to submit abstracts.

Abstracts should be prepared as following:

- An English language abstract must be in the terminology familiar to specialists.
- The text should be succinct and substantive. Beside presenter's full names and affiliations, the abstract must include purpose, methods, results, conclusion and significance.
- Submit a document no longer than 500 words. After consideration and selection by the scientific board, you will be notified if your abstract is considered for poster session or for both poster session and oral communication.

Please select the session in which you consider your abstract would be the most relevant. Nevertheless, scientific board retains the right to decide which session is the most appropriate.

TUESDAY, OCTOBER 17[™]

- Session II Identification and targeting of new tumor vulnerabilities (oral presentation)
- Session III
 Exploration of the primary and secondary tumor microenvironment
 (oral presentation)

WEDNESDAY, OCTOBER 18TH

- Session IV
 New Modalities and Technologies for Pancreatic Cancer Research (oral presentation)
- Session V
 PDAC prevention and early disease (oral presentation)

ABSTRACT SUBMISSION AND OPENING: TUESDAY, MARCH 20^{TH} , 2023 DEADLINE FOR ABSTRACTS SUBMISSION: FRIDAY, SEPTEMBER 6^{TH} , 2023 DETAILS AND SUBMISSION ON www.pcs-afrcp.com

GENERAL INFORMATIONS (



INFORMATION & ORGANIZATION

COM&CO, Johanna GAUDE



POST 15, Bd Grawitz

13016 Marseille, France

TEL +33 (0)4 91 09 70 53 FAX +33 (0)4 96 15 33 08 EMAIL j.gaude@comnco.com CONGRESS VENUE

Domaine du Haut-Carré 43 Rue Pierre Noailles 33400 Talence

REGISTRATION FORM



TO BE RETURN TO:

☐ Dr

☐ Pr

POST COM&CO - 15, Bd Grawitz

13016 Marseille, France

FAX +33 (0)4 96 15 33 08

EMAIL e.jarry@comnco.com j.gaude@comnco.com

Mr

REGISTRATION ONLINE ON WWW.PCS-AFRCP.COM

☐ Ms



Last name	First name
Institution/Company	
Department	
Country	
Phone	Email
	FARI V RIDD FFF0

REGISTRATION FEES	EARLY BIRD FEES UNTIL JULY 31 ST 2023	LATE REGISTRATION
☐ UNDERGRADUATE & GRADUATE STUDENTS	150€	250€
☐ ACADEMIC AND CLINICIAN	400€	550€
CORPORATE (BIOTECH)	500€	600€
☐ CONGRESS DINNER	65€	

PAYMENT

BY CREDIT CARD (Visa, Mastercard (no other card), on protected payment Paybox online form, directly
on the website www.comnco.com. Please indicate y	our name + PCS 2023 in the part : "Additional details".

☐ BY CHECK ENCLOSED (make check in euro payable in France to Com&Co)

☐ BY BANK TRANSFER TO COM&CO EVENTS

Bank: Société Marseillaise de Crédit - IBAN: FR76 3007 7048 8111 7988 0020 038 - BIC: SMCTFR2A

By registering to this congress, we warn you that you accept our general conditions of sale. You can read them here: www.comnco.com/cgv